FROS IN THE NEWS
Dr. Elisa J. Wu Joins FROS Radiation Oncology Cyberknife Center from Memorial Sloan-Kettering
January 23, 2012
FROS Radiation Oncology Cyberknife Center welcomes the addition of Board Certified Radiation Oncologist Dr. Elisa J. Wu. Before joining FROS Radiation Oncology Cyberknife Center, Dr. Elisa J. Wu served as attending physician at Memorial Sloan-Kettering Cancer Center, a world-renowned facility where she had also completed her residency and fellowship. Dr. Elisa J. Wu specializes in the treatment of adult cancers especially breast cancer and her multilingual, being fluent in English, Mandarin Chinese, and Taiwanese. Dr. Wu is an exceptional addition to our already world class team.
FROS IN THE NEWS
Dr. Helen Xiao-Li Joins FROS Radiation Oncology Cyberknife Center
April 2, 2012
We are pleased to announce the appointment of Board Certified Radiation Oncologist Helen Xiao-Li to FROS Radiation Oncology Cyberknife Center. Over the past ten years, she worked as an attending physician for 21st Century Oncology. Dr. Li's fluency in both English and Mandarin Chinese will help us meet the needs of patients in our diverse community.
FROS IN THE NEWS
Cost-Effectiveness Analysis of Stereotactic Body Radiation (SBRT) versus Intensity-Modulated Radiation Therapy (IMRT) For Low or Intermediate Risk Prostate Cancer: A Markov Model Decision Analysis
May 1, 2012
J. C. Hodges, T. Boike, Y. Lotan, R. Benton, D. A. Pistenmaa, H. Choy, R. Timmerman, Department of Radiation Oncology,
University of Texas Southwestern Medical Center, Dallas, TX, Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX
Purpose/Objective(s): In several recent phase I and II clinical trials, stereotactic body radiation therapy (SBRT) for low or intermediate risk prostate cancer has shown high levels of biochemical control and equally low toxicity burden compared to intensity modulated radiation therapy (IMRT). The purpose of this study is to compare the cost effectiveness of two external beam radiation therapy techniques of SBRT and IMRT for low or intermediate risk prostate cancer.
Materials/Methods: A Markov decision tree with probabilistic sensitivity analysis modeling the various disease states of a 70 year old patient with low or intermediate risk prostate cancer was developed. Model assumptions were based on a recent random effects meta-analysis; extensive literature review of costs, utilities, transition rates; and our institutional cost data for evaluation, treatment planning and delivery. Two different prostate radiation techniques were considered: 1) SBRT 35-50 Gy in 5 fractions; 2) IMRT 79.2 Gy in 44 fractions.
Results: The costs for SBRT were analyzed based on delivery with a non robotic linear accelerator consistent with our institution’s SBRT treatment techniques. Given a recent report of 5 year outcomes data with SBRT, the base case assumed equal efficacy and quality of life. At ten years follow up, the Monte Carlo simulation revealed that the mean costs and quality adjusted life years (QALYs) for SBRT and IMRT were $19,155 (7.9) and $32,468 (7.9), respectively. In addition, in order to investigate the effect of relaxing the base case assumptions, sensitivity analysis was performed by varying the efficacy and quality of life of patients treated with SBRT. This sensitivity analysis revealed that a decrease in quality of life of 3.5% or a decrease in efficacy of 8% for patients treated with SBRT would no longer render an incremental cost-effectiveness ratio of <$50,000 per QALY when comparing SBRT to IMRT.
Conclusions: Compared to IMRT, SBRT for low or intermediate prostate cancer has great potential cost savings for our healthcare system and may improve access to radiation, increase patient convenience, and boost quality of life for patients. Our model also suggests that the incremental cost effectiveness ratio of SBRT over IMRT is highly sensitive to quality of life outcomes which should be adequately and comparably measured in current and future prostate SBRT studies.
Author Disclosure: J.C. Hodges: None. T. Boike: None. Y. Lotan: None. R. Benton: None. D.A. Pistenmaa: None. H. Choy: None. R. Timmerman: B. Research Grant; Department of Defense.
FROS IN THE NEWS
FROS Attending Physician Alan Katz, M.D., will present a poster at the 2012 ASTRO meeting and deliver a talk on "5-yr Biochemical Control Rates with SBRT for Organ-Confined Prostate Cancer."
June 1, 2012
Alan Katz, M.D., attending physician at FROS Radiation Oncology Cyberknife Center and internationally renowned prostate cancer radiation oncologist has been selected to present at 2012 International ASTRO conference in Boston this fall. Dr. Katz will present on his findings titled: Five-year Biochemical Control Rates for Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer: A Multi-institutional Pooled Analysis. Dr. Katz has also been selected for a poster viewing during the 2012 ASTRO conference titled: Stereotactic Body Radiation Therapy Offers a Safe, Non-Invasive Treatment for Prostate Cancer Patients over 70 Years Old.